< strong>▎WuXi Contex Content Team Editor

Today, Alnylam Pharmaceuticals, a star company in the RNAi field, announced that the first FDA-approvedThe RNAi therapy patisiran met the primary endpoint in a phase 3 clinical trial of transthyretin-mediated amyloidosis (ATTR-CM) patients with cardiomyopathy. Alnylam noted that the results are for the first time demonstrating the use of RNAi therapy to reduce transthyretin (TTR) expression, is an effective strategy for the treatment of ATTR amyloidosis with cardiomyopathy.

In this randomized, double-blind, placebo-controlled Phase 3 trial, a total of 360 Patients received patisiran or placebo. The results of the trial showed that patisiran met the primary endpoint of the trial. After 12 months of treatment, the 6-minute walking test results of patients receiving patisiran were significantly better than those of the control group compared with baseline (p=0.0162) strong>. In addition, the trial also met secondary endpoints of measures of health-related quality of life assessed using the KCCQ questionnaire. In the composite secondary endpoint of all-cause death and cardiovascular events, patisiran treatment did not show a statistically significant difference (p=0.0574).

Alnylam said detailed results of the study will be reported at a future medical meeting. Meanwhile, the company plans to submit a regulatory application to the U.S. FDA this year. If approved, patisiran is expected to significantly expand the ATTR amyloidosis patient population that could benefit. An article in the industry media Evalute pointed out that the first approved indications for patisiran included about 50,000 patients, and more than 300,000 patients with ATTR amyloidosis with cardiomyopathy.

▲If you have any business needs Please long press to scan the QR code above, or click “Read the original text/Read more” at the end of the article to access the business docking platform and fill in the business requirements information

References:

[1] Alnylam Reports Positive Topline Results from APOLLO -B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy. Retrieved August 3, 2022, from https://investors.alnylam.com/press-release?id=26851

[2] Topline Results from APOLLO -B Phase 3 Study of Patisiran. Retrieved August 3, 2022, from https://alnylampharmaceuticalsinc.gcs-web.com/static-files/dc61b882-9346-4394-9f5c-dd322727742b

[ 3] Alnylam’s heart beats stronger. Retrieved August 3, 2022, from https://www.evaluate.com/vantage/articles/news/trial-results/alnylams-heart-beats-stronger

< p>

Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress. This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec’s position, nor do they represent WuXi AppTec’s support or opposition to the views expressed in this article. This article is also not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Copyright note: This article is from WuXi AppTec content team, you are welcome to forward it to the circle of friends, declined Unauthorized reprinting by media or institutions to other platforms in any form. For reprint authorization, please reply to “Reprint” on the WeChat public account of “WuXi AppTec” for instructions on reprinting.

gif&6Qft00 img>

Share, strong>LikeLike, Watching, focus on global biology Medical health innovation